Aurobindo Pharma Expects First Biosimilar Approval In U.S. In 12-18 Months 
A man rides past an Aurobindo Pharma Ltd. production facility in Jadcherla, India. (Photographer: Prashanth Vishwanathan/Bloomberg)

Aurobindo Pharma Expects First Biosimilar Approval In U.S. In 12-18 Months 

Bookmark
Aurobindo Pharma Ltd. expects its first biosimilar product to receive approval in the U.S. in the next 12-18 months while in Europe it hopes a green signal by 2022, a company official said.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.